Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Chronic myeloid leukemia (CML) has become a chronic and costly disease, since the launch and long-term use of tyrosine kinase inhibitors, including imatinib. Evidence for imatinib�s cost-effectiveness impact were largely based on preference-based quality of life (QoL) measured from randomized controlled trials, however, little is known aboutthe feasibility of QoL measured as a follow-up indicator in real life. This commentary describes our experiences inexploring the QoL measures and attributes influencing QoL in Taiwanese CML patients who were receiving imatinibtreatment.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi